Skip to content

Adherence to ortopaedic shoes

The effect of motivational interviewing combined with digital shoe fitting on adherence to orthopaedic shoes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22073
Enrollment
220
Registered
2019-05-06
Start date
2019-06-03
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer

Interventions

One group will receive motivational interviewing combined digital fitting of orthopaedic shoes and the other group will receive no motivational interviewing combined with traditional fitting of orthop

Sponsors

University of Twente
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are 18 years or older, with a clinical diagnosis of diabetes mellitus type 1 or 2, and with or without previous ulcers or callus, will be included. They are identified with risk profiles 2, 3 or 4, according to the "zorgmodule preventie diabetische voetulcera 2014". Participants in the possession of a prescription for orthopaedic shoes (OSA).

Exclusion criteria

Exclusion criteria: Patients will be excluded if they didn't get a prescription for custom-made orthopaedic shoes, but instead a adaption to convection shoes (OVAC) or semi-orthopaedic shoes (OSB). They will also be excluded if they have an active ulcer, active Charcot, active foot infection or aren't able to walk, or if they are unable to read and understand the study instructions.

Design outcomes

Primary

MeasureTime frame
Proportion patients being adherent.

Secondary

MeasureTime frame
The level of adherence to orthopaedic shoes Complications Patient perspective MI-trained podiatrist perspective Medical consumption Health-related quality of life Cost-effectiveness

Contacts

Public ContactM. Jongebloed-Westra

Universiteit Twente

m.jongebloed-westra@utwente.nl0534896209

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)